A Multicountry, Multicentre, Non-interventional, Retrospective Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer
Metastatic Breast Cancer
n/a - n/a
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Nov 2022 by AstraZeneca
No locations available
Patients who are diagnosed with HER2-positive unresectable or mBC and have received at least 1 LOT in the advanced setting will be included. Approximately a total of 570-830 patients will be enrolled in the study.
Other: None (Observational study)
The data on different types of treatment received by the patients, socio-demographics, and clinico-pathological characteristics and healthcare resource utilisation will be extracted from patients’ medical records (both alive and deceased).
Other Name: Observational study